- Home
- PEO vs TBPH Comparison
PEO vs TBPH Comparison
Compare PEO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEO
- TBPH
- Stock Information
- Founded
- PEO 1929
- TBPH 2013
- Country
- PEO United States
- TBPH United States
- Employees
- PEO N/A
- TBPH N/A
- Industry
- PEO Finance/Investors Services
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- PEO Finance
- TBPH Health Care
- Exchange
- PEO Nasdaq
- TBPH Nasdaq
- Market Cap
- PEO 569.6M
- TBPH 536.5M
- IPO Year
- PEO N/A
- TBPH N/A
- Fundamental
- Price
- PEO $21.86
- TBPH $11.51
- Analyst Decision
- PEO
- TBPH Strong Buy
- Analyst Count
- PEO 0
- TBPH 5
- Target Price
- PEO N/A
- TBPH $16.60
- AVG Volume (30 Days)
- PEO 35.4K
- TBPH 213.7K
- Earning Date
- PEO 01-01-0001
- TBPH 08-04-2025
- Dividend Yield
- PEO 5.93%
- TBPH N/A
- EPS Growth
- PEO N/A
- TBPH N/A
- EPS
- PEO N/A
- TBPH N/A
- Revenue
- PEO N/A
- TBPH $65,266,000.00
- Revenue This Year
- PEO N/A
- TBPH $51.74
- Revenue Next Year
- PEO N/A
- TBPH N/A
- P/E Ratio
- PEO N/A
- TBPH N/A
- Revenue Growth
- PEO N/A
- TBPH 6.11
- 52 Week Low
- PEO $19.22
- TBPH $7.44
- 52 Week High
- PEO $23.80
- TBPH $11.82
- Technical
- Relative Strength Index (RSI)
- PEO 55.97
- TBPH 63.66
- Support Level
- PEO $21.83
- TBPH $11.24
- Resistance Level
- PEO $22.34
- TBPH $11.68
- Average True Range (ATR)
- PEO 0.35
- TBPH 0.29
- MACD
- PEO -0.01
- TBPH 0.01
- Stochastic Oscillator
- PEO 56.76
- TBPH 86.94
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).